These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 9006937
61. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors. Escherich A, Lutz J, Escrieut C, Fourmy D, van Neuren AS, Müller G, Schafferhans A, Klebe G, Moroder L. Biopolymers; ; 56(2):55-76. PubMed ID: 11592053 [Abstract] [Full Text] [Related]
62. Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin. Langer I, Tikhonova IG, Travers MA, Archer-Lahlou E, Escrieut C, Maigret B, Fourmy D. J Biol Chem; 2005 Jun 10; 280(23):22198-204. PubMed ID: 15817487 [Abstract] [Full Text] [Related]
63. Partial agonism by gastrin for a cholecystokinin receptor mediating pepsinogen secretion. Tang LH, Miller MD, Goldenring JR, Modlin IM, Hersey SJ. Am J Physiol; 1993 Nov 10; 265(5 Pt 1):G865-72. PubMed ID: 8238515 [Abstract] [Full Text] [Related]
65. Conformationally readdressed CCK-B/delta-opioid peptide ligands. Nikiforovich GV, Kolodziej SA, Nock B, Bernad N, Martinez J, Marshall GR. Biopolymers; 1995 Oct 10; 36(4):439-52. PubMed ID: 7578939 [Abstract] [Full Text] [Related]
66. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. Charpentier B, Dor A, Roy P, England P, Pham H, Durieux C, Roques BP. J Med Chem; 1989 Jun 10; 32(6):1184-90. PubMed ID: 2724293 [Abstract] [Full Text] [Related]
67. Binding of a phenethyl ester analogue of cholecystokinin to the solubilized pancreatic cholecystokinin receptor: use in ligand-affinity chromatography. Miller LJ, Hadac EM, Gates LK, Gaisano HY. Biochem Biophys Res Commun; 1992 Mar 16; 183(2):396-404. PubMed ID: 1550549 [Abstract] [Full Text] [Related]
69. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity. Cawston EE, Harikumar KG, Miller LJ. Am J Physiol Cell Physiol; 2012 Feb 01; 302(3):C615-27. PubMed ID: 22049215 [Abstract] [Full Text] [Related]
70. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller LJ. J Biol Chem; 1998 May 22; 273(21):12988-93. PubMed ID: 9582333 [Abstract] [Full Text] [Related]
71. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists? Patel S, Chapman KL, Smith AJ, Bailey I, Freedman SB. Regul Pept; 1996 Aug 27; 65(1):29-35. PubMed ID: 8876033 [Abstract] [Full Text] [Related]
72. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor. Smeets RL, Fouraux MA, Pouwels W, van Emst-de Vries SE, Ronken E, De Pont JJ, Willems PH. Br J Pharmacol; 1998 Jul 27; 124(5):935-45. PubMed ID: 9692779 [Abstract] [Full Text] [Related]
73. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ. J Med Chem; 1999 Jun 17; 42(12):2105-11. PubMed ID: 10377216 [Abstract] [Full Text] [Related]
74. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds. Rodriguez M, Lignon MF, Galas MC, Fulcrand P, Mendre C, Aumelas A, Laur J, Martinez J. J Med Chem; 1987 Aug 17; 30(8):1366-73. PubMed ID: 2441054 [Abstract] [Full Text] [Related]
75. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin. Foucaud M, Archer-Lahlou E, Marco E, Tikhonova IG, Maigret B, Escrieut C, Langer I, Fourmy D. Regul Pept; 2008 Jan 10; 145(1-3):17-23. PubMed ID: 17961734 [Abstract] [Full Text] [Related]
76. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ. Mol Pharmacol; 2002 May 10; 61(5):1041-52. PubMed ID: 11961122 [Abstract] [Full Text] [Related]
77. On the biologically active structures of cholecystokinin, little gastrin, and enkephalin in the gastrointestinal system. Pincus MR, Carty RP, Chen J, Lubowsky J, Avitable M, Shah D, Scheraga HA, Murphy RB. Proc Natl Acad Sci U S A; 1987 Jul 10; 84(14):4821-5. PubMed ID: 3037525 [Abstract] [Full Text] [Related]
78. Cholecystokinin octapeptide analogues stable to brain proteolysis. Knight M, Barone P, Tamminga CA, Steardo L, Chase TN. Peptides; 1985 Jul 10; 6(4):631-4. PubMed ID: 2999729 [Abstract] [Full Text] [Related]
79. Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. Jagerschmidt A, Guillaume N, Roques BP, Noble F. Mol Pharmacol; 1998 May 10; 53(5):878-85. PubMed ID: 9584214 [Abstract] [Full Text] [Related]
80. Modulation of cholecystokinin activity by albumin. Huang SC, Talkad VD, Fortune KP, Jonnalagadda S, Severi C, Delle Fave G, Gardner JD. Proc Natl Acad Sci U S A; 1995 Oct 24; 92(22):10312-6. PubMed ID: 7479774 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]